Nurix, Inc. is a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that directs protein degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology. Nurix's state-of-the-art product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures and The Column Group.

Key Contact